Dentsply Sirona Inc.

XRAY

Nasdaq; healthcare; SIC 3843, Dental Equipment & Supplies; CIK 0000818479

D

fourth fifth of 305 graded peers in healthcare

rank 206 of 305; percentile 67.4; sampling error 2.8 points; lower is stronger


A B C D E

D, the sloth



Scoreboard	
Profitability	B percentile 35.1
Solvency	C/D percentile 60.8
Growth and financing	D percentile 65.2
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $5.4B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	9 of 13
Graded from	filings received through Feb 26, 2026 264 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$8.95 2026-11-16; market equity $1.8B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") is the world's largest diversified manufacturer of professional dental products and technologies, with a 139-year history of innovation and service to the dental industry and a vision of improving oral health and continence care globally. Dentsply Sirona develops, manufactures, and markets comprehensive solutions, including technologically advanced dental equipment supported by cloud-enabled software solutions as well as dental products and healthcare consumable products in urology and enterology under a strong portfolio of world-class brands.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 35.1						
Gross profitability	33.9%	32.8%		41.4	346	2025-12-31
Return on invested capital	not computable	9.6%				


pretax income must exceed the validity floor and imply a 0%-100% tax rate

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(14.9%)	(6.7%)	28.6	756	2025-12-31
Gross margin stability, five years	1.9 pts	2.8 pts	35.2	237	2025-12-31
Solvency, sleeve percentile 60.8					
Altman Z double-prime	(0.30)	0.31	38.9	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(3.61x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	1.51x	2.68x	82.7	781	2025-12-31
Growth and financing, sleeve percentile 65.2					
Revenue growth, three-year compound	(2.1%)	9.6%	76.2	400	2025-12-31
Free cash flow growth, three-year compound	(34.4%)	11.1%	96.8	94	2025-12-31
Reinvestment rate	not computable	33.9%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	(10.8%)	3.2%	70.7	663	2025-12-31
Net share issuance, one year	0.4%	1.6%	17.0	624	2026-02-20

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
201	Organogenesis Holdings Inc. (ORGO)	65.8	D	fortress balance sheet
202	Royalty Pharma plc (RPRX)	66.1	D	
203	Entera Bio Ltd. (ENTX)	66.4	D	degenerate inputs
204	PTC Therapeutics, Inc. (PTCT)	66.8	D	
205	Fulgent Genetics, Inc. (FLGT)	67.1	D	
206	Dentsply Sirona Inc. (XRAY)	67.4	D	
207	Angiodynamics Inc. (ANGO)	67.8	D	fortress balance sheet
208	Exagen Inc. (XGN)	68.1	D	dilution, fortress balance sheet
209	American Shared Hospital Services (AMS)	68.4	D	late filer
210	Adaptive Biotechnologies Corp. (ADPT)	68.8	D	
211	U S Physical Therapy Inc. (USPH)	69.1	D	

What the price implies

at the 2026-11-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(28.7%)	(1.7%)	31
Distance from 52-week high	(39.1%)	(31.5%)	42
EBIT to enterprise value	(11.0%)	0.5%	28
Free cash flow yield	5.9%	0.5%	83
Book value to price	0.76	0.28	79
Sales to price	2.08	0.36	88
Composite equity issuance, five years	(21.1%)	13.2%	9

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Relative strength against the sector, log excess return	(0.51)	(0.19)	31
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$195.0M
Operating cash flow, four quarters	$272.0M
Months of runway	not finite
Days since last periodic filing	12 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$40.0M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$1.8B	2025-12-31	2026-02-26	10-K	26-000075
2	assets	us-gaap:Assets	$5.4B	2025-12-31	2026-02-26	10-K	26-000075
3	operating income	us-gaap:OperatingIncomeLoss	-$422.0M	2025-12-31	2026-02-26	10-K	26-000075
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$486.0M	2025-12-31	2026-02-26	10-K	26-000075
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$112.0M	2025-12-31	2026-02-26	10-K	26-000075
6	total debt	us-gaap:LongTermDebt	$2.3B	2025-12-31	2026-02-26	10-K	26-000075
7	book equity	us-gaap:StockholdersEquity	$1.3B	2025-12-31	2026-02-26	10-K	26-000075
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$326.0M	2025-12-31	2026-02-26	10-K	26-000075
9	total debt	us-gaap:LongTermDebt	$1.7B	2024-12-31	2025-02-27	10-K	25-000035
10	book equity	us-gaap:StockholdersEquity	$1.9B	2024-12-31	2026-02-26	10-K	26-000075
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$272.0M	2024-12-31	2026-02-26	10-K	26-000075
12	net income	us-gaap:NetIncomeLoss	-$598.0M	2025-12-31	2026-02-26	10-K	26-000075
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$235.0M	2025-12-31	2026-02-26	10-K	26-000075
14	assets	us-gaap:Assets	$5.8B	2024-12-31	2026-02-26	10-K	26-000075
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.7B	2025-12-31	2026-02-26	10-K	26-000075
16	gross profit	us-gaap:GrossProfit	$2.0B	2024-12-31	2026-02-26	10-K	26-000075
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.8B	2024-12-31	2026-02-26	10-K	26-000075
18	gross profit	us-gaap:GrossProfit	$2.1B	2023-12-31	2026-02-26	10-K	26-000075
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.0B	2023-12-31	2026-02-26	10-K	26-000075
20	gross profit	us-gaap:GrossProfit	$2.1B	2022-12-31	2025-02-27	10-K	25-000035
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.9B	2022-12-31	2025-02-27	10-K	25-000035
22	gross profit	us-gaap:GrossProfit	$2.3B	2021-12-31	2024-02-29	10-K	24-000021
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.2B	2021-12-31	2024-02-29	10-K	24-000021
24	current assets	us-gaap:AssetsCurrent	$2.0B	2025-12-31	2026-02-26	10-K	26-000075
25	current liabilities	us-gaap:LiabilitiesCurrent	$1.3B	2025-12-31	2026-02-26	10-K	26-000075
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.6B	2025-12-31	2026-02-26	10-K	26-000075
27	liabilities	us-gaap:Liabilities	$4.1B	2025-12-31	2026-02-26	10-K	26-000075
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$352.0M	2025-12-31	2026-02-26	10-K	26-000075
29	operating income	us-gaap:OperatingIncomeLoss	-$85.0M	2023-12-31	2026-02-26	10-K	26-000075

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	interest expense	us-gaap:InterestExpense	$81.0M	2023-12-31	2024-02-29	10-K	24-000021
31	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$131.0M	2025-12-31	2026-02-26	10-K	26-000075
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$461.0M	2024-12-31	2026-02-26	10-K	26-000075
33	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$180.0M	2024-12-31	2026-02-26	10-K	26-000075
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$377.0M	2023-12-31	2026-02-26	10-K	26-000075
35	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$149.0M	2023-12-31	2026-02-26	10-K	26-000075
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$517.0M	2022-12-31	2025-02-27	10-K	25-000035
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$149.0M	2022-12-31	2023-08-07	10-K/A	23-000062
38	current assets	us-gaap:AssetsCurrent	$1.7B	2024-12-31	2026-02-26	10-K	26-000075
39	current liabilities	us-gaap:LiabilitiesCurrent	$1.6B	2024-12-31	2026-02-26	10-K	26-000075
40	assets	us-gaap:Assets	$7.4B	2023-12-31	2025-02-27	10-K	25-000035
41	assets	us-gaap:Assets	$7.6B	2022-12-31	2024-02-29	10-K	24-000021
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	199,749,333	2026-02-20	2026-02-26	10-K	26-000075
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	198,991,963	2025-02-14	2025-02-27	10-K	25-000035

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.